Blog

CRISPR/Cas9 – ATTR Clinical Trial Update

November 17, 2022

Per the National Institute of Health, “One of the most promising areas of research in recent years has been gene editing, including CRISPR/Cas9, for fixing misspellings in genes to treat or even cure many conditions.” In this piece we provide a clinical trial update for transthyretin (TTR) amyloidosis using this technology.

Heart Failure & Amyloidosis

October 27, 2022

Heart failure occurs when the heart muscle doesn’t pump blood as well as it should. Many medical conditions that damage the heart muscle can cause heart failure, such as Coronary artery disease, Heart attack, Obesity, Kidney disease, Diabetes, and Cardiomyopathy. Here we summarize how cardiac amyloidosis is associated with heart failure.

Over 10,000 medical students and residents!!

October 25, 2022

The Amyloidosis Speakers Bureau has now presented to over 10,000 medical students and residents!

Int’l Symposium on Amyloidosis (ISA) – Heidelberg 2022

September 12, 2022

We are super proud to have presented the story about the Amyloidosis Speakers Bureau at last week’s International Symposium on Amyloidosis (ISA) in Heidelberg, Germany.

FDA Drug Approval Process

August 24, 2022

Drugs are the lifeblood of patient treatments, and the development of new drugs is critical. Overseen by the FDA (U.S. Food and Drug Administration), in this blog we outline the phases and 12 steps required to develop and approve drugs.